Advisory Committee on Immunization Practices, 45905 [2023-15190]

Download as PDF Federal Register / Vol. 88, No. 136 / Tuesday, July 18, 2023 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2023–0063] Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice and request for comment. AGENCY: In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment. DATES: The meeting will be held on August 3, 2023, 11 a.m. to 3:30 p.m., EDT (date and times subject to change; see the ACIP website for updates: https://www.cdc.gov/vaccines/acip/ index.htm). Written comments will be received July 19, 2023–August 2, 2023. ADDRESSES: You may submit comments, identified by Docket No. CDC–2023– 0063, by either of the methods listed below. CDC does not accept comments by email. • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. • Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Attn: Docket No. CDC– 2023–0063. Instructions: All submissions received must include the Agency name and docket number. All relevant comments received in conformance with the https://www.regulations.gov suitability policy will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. The meeting will be webcast live via the World Wide Web. The webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/ index.html. ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management Specialist, Advisory Committee on Immunization Practices, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 VerDate Sep<11>2014 19:16 Jul 17, 2023 Jkt 259001 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Telephone: (404) 639–8836; Email: ACIP@cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The Advisory Committee on Immunization Practices (ACIP) is charged with advising the Director, Centers for Disease Control and Prevention (CDC), on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines For Children program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under applicable provisions of the Affordable Care Act and section 2713 of the Public Health Service Act, immunization recommendations of ACIP that have been approved by the Director, CDC, and appear on CDC immunization schedules generally must be covered by applicable health plans. Matters to be Considered: The agenda will include discussion of nirsevimab for prevention of respiratory syncytial virus (RSV). A recommendation vote and a Vaccines for Children vote are scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit https://www.cdc.gov/vaccines/acip/ meetings/. Meeting Information: The meeting will be webcast live via the World Wide Web. For more information on ACIP, please visit the ACIP website: https:// www.cdc.gov/vaccines/acip/. Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ PO 00000 Frm 00024 Fmt 4703 Sfmt 9990 45905 near-duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. Written Public Comment: The docket will be opened to receive written comments on July 19, 2023. Written comments must be received August 2, 2023. Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below. Procedure for Oral Public Comment: All persons interested in making an oral public comment at the August 3, 2023, ACIP meeting must submit a request at https://www.cdc.gov/vaccines/acip/ meetings/ no later than 11:59 p.m., EDT, August 1, 2023, according to the instructions provided. If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email on August 2, 2023. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to three minutes, and each speaker may only speak once per meeting. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2023–15190 Filed 7–17–23; 8:45 am] BILLING CODE 4163–18–P E:\FR\FM\18JYN1.SGM 18JYN1

Agencies

[Federal Register Volume 88, Number 136 (Tuesday, July 18, 2023)]
[Notices]
[Page 45905]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-15190]



[[Page 45905]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2023-0063]


Advisory Committee on Immunization Practices

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with regulatory provisions, the Centers for 
Disease Control and Prevention (CDC) announces the following meeting of 
the Advisory Committee on Immunization Practices (ACIP). This meeting 
is open to the public. Time will be available for public comment.

DATES: The meeting will be held on August 3, 2023, 11 a.m. to 3:30 
p.m., EDT (date and times subject to change; see the ACIP website for 
updates: https://www.cdc.gov/vaccines/acip/index.htm).
    Written comments will be received July 19, 2023-August 2, 2023.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2023-
0063, by either of the methods listed below. CDC does not accept 
comments by email.
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, 
Atlanta, Georgia 30329-4027. Attn: Docket No. CDC-2023-0063.
    Instructions: All submissions received must include the Agency name 
and docket number. All relevant comments received in conformance with 
the https://www.regulations.gov suitability policy will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov.
    The meeting will be webcast live via the World Wide Web. The 
webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/.

FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management 
Specialist, Advisory Committee on Immunization Practices, National 
Center for Immunization and Respiratory Diseases, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta, 
Georgia 30329-4027. Telephone: (404) 639-8836; Email: [email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The Advisory Committee on Immunization Practices (ACIP) is 
charged with advising the Director, Centers for Disease Control and 
Prevention (CDC), on the use of immunizing agents. In addition, under 
42 U.S.C. 1396s, the Committee is mandated to establish and 
periodically review and, as appropriate, revise the list of vaccines 
for administration to vaccine-eligible children through the Vaccines 
For Children program, along with schedules regarding dosing interval, 
dosage, and contraindications to administration of vaccines. Further, 
under applicable provisions of the Affordable Care Act and section 2713 
of the Public Health Service Act, immunization recommendations of ACIP 
that have been approved by the Director, CDC, and appear on CDC 
immunization schedules generally must be covered by applicable health 
plans.
    Matters to be Considered: The agenda will include discussion of 
nirsevimab for prevention of respiratory syncytial virus (RSV). A 
recommendation vote and a Vaccines for Children vote are scheduled. 
Agenda items are subject to change as priorities dictate. For more 
information on the meeting agenda, visit https://www.cdc.gov/vaccines/acip/meetings/.
    Meeting Information: The meeting will be webcast live via the World 
Wide Web. For more information on ACIP, please visit the ACIP website: 
https://www.cdc.gov/vaccines/acip/.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or supporting 
materials that you consider confidential or inappropriate for public 
disclosure. If you include your name, contact information, or other 
information that identifies you in the body of your comments, that 
information will be on public display. CDC will review all submissions 
and may choose to redact, or withhold, submissions containing private 
or proprietary information such as Social Security numbers, medical 
information, inappropriate language, or duplicate/near-duplicate 
examples of a mass-mail campaign. CDC will carefully consider all 
comments submitted into the docket.
    Written Public Comment: The docket will be opened to receive 
written comments on July 19, 2023. Written comments must be received 
August 2, 2023.
    Oral Public Comment: This meeting will include time for members of 
the public to make an oral comment. Priority will be given to 
individuals who submit a request to make an oral public comment before 
the meeting according to the procedures below.
    Procedure for Oral Public Comment: All persons interested in making 
an oral public comment at the August 3, 2023, ACIP meeting must submit 
a request at https://www.cdc.gov/vaccines/acip/meetings/ no 
later than 11:59 p.m., EDT, August 1, 2023, according to the 
instructions provided.
    If the number of persons requesting to speak is greater than can be 
reasonably accommodated during the scheduled time, CDC will conduct a 
lottery to determine the speakers for the scheduled public comment 
session. CDC staff will notify individuals regarding their request to 
speak by email on August 2, 2023. To accommodate the significant 
interest in participation in the oral public comment session of ACIP 
meetings, each speaker will be limited to three minutes, and each 
speaker may only speak once per meeting.
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-15190 Filed 7-17-23; 8:45 am]
BILLING CODE 4163-18-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.